Scisparc

Scisparc Acquisitions (Net)

The Acquisitions (Net) of Scisparc (SPRC) as of Oct 16, 2026 is -1.63 M USD. In the previous year, Acquisitions (Net) was -1.11 M USD — a change of 46.85% (lower).

Acquisitions (Net)

-1.63 MUSD

YoY

46.85%

Last updated:

Acquisitions (Net) of Scisparc is 2024 -1.63 M USD. Acquisitions (Net) of Scisparc was 2023 -1.11 M USD. It decreases by 46.85% lower compared to the previous year.

The Scisparc Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2017
-10,000.00 USD
Jan 1, 2018
-2.08 M USD
Jan 1, 2019
1.27 M USD
Jan 1, 2020
20,000.00 USD
Jan 1, 2021
-40,000.00 USD
Jan 1, 2022
-2.22 M USD
Jan 1, 2023
-1.11 M USD
Jan 1, 2024
-1.63 M USD
The Scisparc Acquisitions (Net) history
YEARAcquisitions (Net)YoY
-1.63 MUSD+46.85%
-1.11 MUSD-50.00%
-2.22 MUSD+5,450.00%
-40,000.00USD-300.00%
20,000.00USD-98.43%
1.27 MUSD-161.06%
-2.08 MUSD+20,700.00%
-10,000.00USD—
0.00USD—
0.00USD-100.00%
-100,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? Scisparc Ltd., listed under the ticker SPRC with ISIN IL0010951403, is a biotechnology company headquartered in Tel Aviv-Yafo, Israel. The company operates in the healthcare sector and has a workforce of three employees. Scisparc Ltd. went public through an IPO on December 22, 2021. Its website is https://scisparc.com/. The company is engaged in the development of pharmaceutical products based on cannabinoid technologies, focusing on repurposing dronabinol for various medical conditions. Specific drug development programs include THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain treatment. Scisparc Ltd. is a clinical stage pharmaceutical company, indicating its focus on advancing drug candidates through clinical trials toward potential regulatory approval and commercialization. The company's activities are centered around leveraging cannabinoid-based approaches to address unmet medical needs in multiple therapeutic areas. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

Acquisitions (Net) of Scisparc is -1.63 M USD in 2024.

Acquisitions (Net) of Scisparc changed from -1.11 M USD to -1.63 M USD, representing a 46.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Scisparc since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Scisparc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Scisparc

All Key Metrics — Scisparc